Which ASX 200 healthcare share with AI upside just hit a new 52-week high?

And top broker Goldman Sachs says the share price can go even higher.

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX 200 healthcare stock Pro Medicus Limited (ASX: PME) reached a new all-time high of $113.93 per share on Friday.

Pro Medicus shares closed at $113.52 yesterday, up 1.27%. The medical imaging company has had an incredible run over the past year, with its share price rising 88.5%.

And top broker Goldman Sachs reckons this ASX 200 healthcare share has got further room to run.

The broker has a buy rating on Pro Medicus shares with a 12-month price target of $134, implying a potential 18% upside for investors who buy today.

'Best in class tech'

Goldman Sachs describes Pro Medicus as having "best in class tech in a growth market with artificial intelligence (AI) upside".

Pro Medicus provides sophisticated software enabling radiologists and doctors to view high-quality medical images remotely or in their offices.

Demand for medical imaging is growing, especially as the world's population ages and medical advancements enable better testing.

On top of that, a shortage of radiologists means healthcare companies are keen to adopt technology that enables them to hire radiologists in remote locations, or those working from home, to read tests.

Goldman says Pro Medicus' flagship radiology product, Visage 7, has become a core product for many healthcare institutions.

In a new note published this week, Goldman said:

We believe Visage 7 is core to many healthcare institutions given its distinct speed and cloud capabilities, and we forecast the company to gain market share from c7% today to 13% by 2030E.

The broker is also positive on this ASX 200 healthcare share because of the market's AI upside.

In another note, Goldman explained the impact of AI in the medical imaging space:

AI opens an incremental US$620mn TAM today (growing at a +34.7% CAGR) with radiology receiving the majority (c.80%) of recent FDA AI algorithm clearance.

We believe PME is well positioned to take share as the incumbent viewing platform across many large, and likely early adopters of new technology.

PME is generating revenue from its Visage breast density AI algorithm … today, and we see the potential value for AI to be significant with adoption driven by improved accuracy and clinical outcomes.

We forecast AI to comprise 9% of PME's revenue by FY30E (from <1% in FY25E), with upside if PME achieves faster AI attach penetration, higher price per scan, and a greater proportion of algorithms developed in-house where no royalties are paid to a partner.

Pro Medicus continues to expand

Pro Medicus has won many long-term contracts with major healthcare institutions around the world, and as it continues to expand, so does its earnings.

In its 1H FY24 results, Pro Medicus revealed a 30.3% increase in revenue to $74.1 million and a 33.3% lift in net profit to $36.3 million.

The company also had $131.5 million in cash and other financial assets as of 31 December, up 8.3%.

During the half, Pro Medicus won four new key contracts worth a total of $200 million. The contracts have committed minimum exam volumes and terms ranging from seven to 10 years.

ASX 200 healthcare share snapshot

Pro Medicus moved into the ASX 100 during the S&P DJI March quarterly rebalance.

The ASX 200 healthcare share has risen 478% over the past five years.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Resmed share price higher despite CEO hitting sell on 14,683 shares

ResMed's CEO just sold $4.8 million worth of his own company's shares.

Read more »